Bevacizumab biosimilar - Genor Biopharma
Alternative Names: GB 222Latest Information Update: 12 Jan 2022
Price :
$50 *
At a glance
- Originator Genor Biopharma
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Non-small cell lung cancer
Most Recent Events
- 24 May 2020 Phase III development for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, In adults, In the elderly) is still ongoing in China (ChiCTR-IIR-17013100)
- 24 Oct 2017 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Recurrent, Combination therapy, In adults, In the elderly) in China (IV) (ChiCTR-IIR17013100)
- 01 Dec 2016 Phase-I clinical trials in Cancer (In volunteers) in China (IV) (ChiCTR-IIR17011143)